Nebulized Ketamine for the Treatment of Major Depressive Disorder
NCT06752759
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Severe Depression
- Moderate Depression
- Ketamine
- Midazolam
- Peripheral Nervous System Agents
- Central Nervous System Agents
- Neurotransmitter Agents
- Physiologic Effects of Drugs
- Sensory System Agents
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents, Non-Steroidal
- Depressive Symptom
- Hypnotics and Sedatives
- Anti-anxiety Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anesthetics Agent
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 88 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Theresa Jacob, PhD, MPH
- Last updated on ClinicalTrials.gov
- April 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Maimonides Medical Center · Brooklyn, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.